Researchers have described a novel primary immunodeficiency due to a mutation in AIOLOS. This acts through a novel pathogenic mechanism termed 'heterodimeric interference', whereby when two different ...

Over the span of five months, biotechnology startup Aiolos Bio launched, raised initial funding from venture investors and negotiated a $1 billion buyout by GSK. The acquisition, announced by GSK on ...

SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Aiolos Bio, Inc., (“Aiolos” or “the Company) a clinical-stage biotechnology company focused on addressing the unmet treatment needs of patients with ...

A consistent theme of 2023 has been that advanced assets attract seismic capital and a newly launched biotech adds more proof to the pile. Aiolos Bio is jetting out of stealth with a $245 million ...

GSK Plc agreed to buy the closely held US biotech Aiolos Bio Inc., spending as much as $1.4 billion to gain a promising respiratory medicine. Aiolos has an experimental drug ready to enter mid-stage ...

There ain’t no rest for the wicked when it comes to dealmaking at the 2024 J.P. Morgan Healthcare Conference. Shortly after several Big Pharma names like Johnson & Johnson, Merck and Novartis ...

GSK GSK-1.83%decrease; red down pointing triangle is buying biopharmaceutical company Aiolos Bio for up to $1.4 billion in a deal that expands its respiratory pipeline and follows a string of ...

Tokyo, Japan - Primary immunodeficiencies, such as severe combined immunodeficiency disease (SCID), occur when the immune system does not work properly, leading to increased susceptibility to various ...